The Cambridge-based startup is developing molecular diagnostic technology designed to deliver actionable results in approximately 15 minutes.
Nanopath has announced $25 million in Series B financing, including $2 million in non-dilutive grant funding.
The financing was co-led by Norwest and SV Health Investors' MedTech Convergence Fund, with participation from Labcorp Venture Fund and additional investors.
The company was co-founded by scientists Alison Burklund and Amogha Tadimety, who serve as co-CEOs.
Reducing the Wait for Diagnostic Results
Conventional molecular testing can require laboratory processing, specialized equipment and follow-up appointments.
Nanopath is developing a point-of-care diagnostic platform intended to provide laboratory-quality molecular analysis during a clinical visit.
Its lead application is a test for vaginitis designed to produce results in approximately 15 minutes.
The technology uses a proprietary biosensing approach that aims to detect molecular targets without traditional PCR amplification.
From Research to Commercialization
The new financing will support manufacturing scale-up, team expansion and an FDA 510(k) clinical study.
Nanopath also plans to expand its technology toward other indications, including urinary tract infections and sexually transmitted infections.
Its commercial opportunity depends on making accurate diagnostic testing accessible in more clinical settings.
However, its lead product still faces regulatory and validation milestones before broad commercialization.
The next challenge is establishing clinical performance and demonstrating that faster testing can improve care delivery while remaining affordable for providers and patients.
Founders: Alison Burklund and Amogha Tadimety. Investors: Norwest, SV Health Investors, Labcorp Venture Fund and others.